U.S. COMPANY FILING
VERTEX PHARMACEUTICALS INC / MA — Form 10-K filed 2026-02-13
Filing text preview
Vertex Pharmaceuticals reported strong 2025 results with product revenue growth. CASGEVY generated $115.8 million in revenue from 64 patient infusions. Cash and marketable securities increased to $12.3 billion. The company repurchased $618.5 million of stock. VX-264 program was discontinued, leading to a $379.0 million impairment charge. Effective tax rate was 14.9% in 2025 versus 315.5% in 2024. The company plans to expand commercialization of JOURNAVX and povetacicept in 2026.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record